Shopping Cart
- Remove All
- Your shopping cart is currently empty
Biricodar dicitrate (VX-710) is a potent MDR inhibitor with no anticancer activity and can be used to study prostate cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | 492 € | In Stock | |
5 mg | 1.111 € | In Stock | |
25 mg | 1.824 € | In Stock | |
50 mg | 2.261 € | 6-8weeks | |
100 mg | 2.945 € | 6-8weeks |
Description | Biricodar dicitrate (VX-710) is a potent MDR inhibitor with no anticancer activity and can be used to study prostate cancer. |
Targets&IC50 | Iodoaryl azido-prazosin:0.55 μM(EC50), P-gp:0.75uM(EC50) |
In vitro | Biricodar exhibits activity against both P-glycoprotein (Pgp) and MRP-1, enhancing drug uptake and retention while reversing drug resistance mediated by wild-type BCRP (BCRPR482). In Pgp-expressing 8226/Dox6 cells, biricodar increases the uptake of mitoxantrone and daunorubicin by 55% and 100%, respectively. It enhances their retention by 100% and 60%, respectively, and boosts their cytotoxicity by 3.1- and 6.9-fold, respectively. Furthermore, biricodar has similar effects on HL60/Adr cells (MRP-1) and 8226/MR20 cells (BCRP(R482)), but it has little impact on MCF7 AdVP3000 cells (BCRP(R482T))[1]. VX-710, a non-macrocyclic pipecolinate derivative binding to the FK506 receptor protein, has been shown to restore sensitivity in various multidrug-resistant cells, including myeloma, melanoma, carcinoma, and leukemia[2]. Additionally, biricodar effectively inhibits the photoaffinity labeling of P-glycoprotein by [3H]azidopine or [125I]iodoaryl azido-prazosin, with EC50 values of 0.75 and 0.55 μM[3]. |
Alias | VX 710-3 |
Molecular Weight | 987.95 |
Formula | C46H57N3O21 |
Cas No. | 174254-13-8 |
Smiles | OC(CC(C(O)=O)(O)CC(O)=O)=O.O=C(C1=CC(OC)=C(C(OC)=C1)OC)C(N2[C@@H](CCCC2)C(OC(CCCC3=CN=CC=C3)CCCC4=CN=CC=C4)=O)=O.OC(CC(C(O)=O)(O)CC(O)=O)=O |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.